New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
08:18 EDTAZN, BCSAstraZeneca, Barclays investors push back on executive pay, Telegraph says
38.5% of AstraZeneca (AZN) shareholders voted against the company's executive pay plan, while 24% of investors voted against Barclays' (BCS) pay plan, reported The Telegraph. "We are disappointed with today's vote. As a priority we will be seeking to understand what concerns lay behind this," said an AstraZeneca spokesman. Reference Link
News For AZN;BCS From The Last 14 Days
Check below for free stories on AZN;BCS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
August 18, 2014
07:57 EDTAZNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 14, 2014
12:01 EDTAZNThird Point gives quarterly update on stakes
NEW STAKES: Rackspace (RAX), Finisar (FNSR), Amgen (AMGN), Ally Financial (ALLY), and AstraZeneca (AZN). INCREASED STAKES: Dollar General (DG) and Dow Chemical (DOW). DECREASED STAKES: FedEx (FDX), Hertz (HTZ), T-Mobile (TMUS) and Intrexon (XON). LIQUIDATED STAKES: Google Class A (GOOGL), Verizon (VZ) and Mondelez (MDLZ).
06:18 EDTBCSNASDAQ, CME Group eyes Barclays index division, Bloomberg says
Subscribe for More Information
August 13, 2014
13:35 EDTBCSBarclays index division eyed by Bloomberg, Markit, WSJ says
Barclay's fixed-income index division is being eyed by both Bloomberg and Markit as a potential acquisition, according to The Wall Street Journal, citing people familiar with the matter. The sources said that the offers being discussed are falling around $1B and other possible bidders are still keeping tabs on the talks. Reference Link
08:31 EDTAZNAstraZeneca says Phase 3 trials of lesinurad for gout met primary endpoints
AstraZeneca announced top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor, as a combination therapy for the treatment of patients with symptomatic gout. Lesinurad is an investigational agent that inhibits the URAT1 transporter, increasing uric acid excretion and thereby lowering serum uric acid. In the CLEAR1 and CLEAR2 trials, both lesinurad 200mg and 400mg in combination with allopurinol met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0mg/dL at month 6 compared to allopurinol alone. In the CRYSTAL trial, lesinurad 400mg in combination with febuxostat met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <5.0mg/dL at month 6 compared to febuxostat alone. Although lesinurad 200mg did not achieve statistical significance at month 6, this dose in combination with febuxostat, was superior to placebo plus febuxostat at all other time points. Results from these Phase III clinical trials will be submitted to a scientific meeting later in 2014. The company is proceeding with preparation of regulatory submissions for lesinurad 200mg combination therapy.
06:31 EDTBCSAnalyst says Barclays up against $2B in crime expenses, Bloomberg says
Sanford C. Bernstein analyst Chirantan Barua said that Barclays is up against expenses worth as much as $2B for supposedly fixing currency markets, being untruthful to customers about its U.S. dark pool trading and mis-selling interest-rate swaps, according to Bloomberg, citing comments from Barua. Barua said that the firm could finalize settlements by the end of the year. Reference Link
August 12, 2014
05:58 EDTAZNStocks with implied volatility movement; P AZN
Subscribe for More Information
August 11, 2014
07:22 EDTBCSHSBC will not follow Barclays in rolling private bank into retail biz, FT says
HSBC (HSBC) CEO Stuart Gulliver has pledged to retain his group’s private bank as a standalone division and will not go the way of rival Barclays’ (BCS), which combined its private banking operation into its retail division in May, said Financial Times. Reference Link
August 7, 2014
06:13 EDTAZNDynavax says AZD1419 Phase 1 study met secondary endpoints
Subscribe for More Information
August 6, 2014
09:19 EDTAZNShire, AstraZeneca, Smith & Nephew slump amid inversion fears, FT says
Subscribe for More Information
08:20 EDTBCSFed, FDIC tell big banks to revise 'living will' plans
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use